These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34768625)

  • 1. Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain.
    Plata A; Guerrero-Ramos F; Garcia C; González-Díaz A; Gonzalez-Valcárcel I; de la Morena JM; Díaz-Goizueta FJ; Del Álamo JF; Gonzalo V; Montero J; Sousa-Escandón A; León J; Pontones JL; Delgado F; Adriazola M; Pascual Á; Calleja J; Ruano A; Martínez-Piñeiro L; Angulo JC
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer.
    Magalhães JC; Sousa M; Basto R; Fraga T; Gomes I; Fernandes C; Mariano M; Paulo J; Madeira P; Sousa G
    Cureus; 2023 Sep; 15(9):e45672. PubMed ID: 37745737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperthermic intravesical chemotherapy with mitomycin-C for the treatment of high-risk non-muscle-invasive bladder cancer patients.
    Conroy S; Pang K; Jubber I; Hussain SA; Rosario DJ; Cumberbatch MG; Catto JWF; Noon AP
    BJUI Compass; 2023 May; 4(3):314-321. PubMed ID: 37025474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.
    Guerrero-Ramos F; González-Padilla DA; González-Díaz A; de la Rosa-Kehrmann F; Rodríguez-Antolín A; Inman BA; Villacampa-Aubá F
    World J Urol; 2022 Apr; 40(4):999-1004. PubMed ID: 35037963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage.
    Grimberg DC; Dudinec J; Shah A; Inman BA
    Urol Oncol; 2021 Aug; 39(8):498.e13-498.e20. PubMed ID: 33485761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
    Angulo JC; Álvarez-Ossorio JL; Domínguez-Escrig JL; Moyano JL; Sousa A; Fernández JM; Gómez-Veiga F; Unda M; Carballido J; Carrero V; Fernandez-Aparicio T; García de Jalón Á; Solsona E; Inman B; Palou J
    Eur Urol Oncol; 2023 Feb; 6(1):58-66. PubMed ID: 36435738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing adverse effects, short term outcomes, and cost implications of hyperthermic intravesical chemotherapy with Mitomycin-C and intravesical bacillus Calmette-Guerin instillation (Moscow-I strain) in the management of intermediate and high-risk nonmuscle invasive bladder cancer.
    Thyavihally YB; Waigankar SS; Dev P; Asari A; Pednekar AP; Athikari N; Raut A; Khandekar A; Badlani N
    Urol Ann; 2021; 13(4):424-430. PubMed ID: 34759657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.
    Arrabal Polo MÁ; Melgarejo Segura MT; Yáñez Castillo Y; Morales Martínez A; Pareja Vílchez M; Arrabal Martín M
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7453-7459. PubMed ID: 36952006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis.
    Pazir Y; Esmeray A; Caglar U; Erbin A; Ozgor F; Sarilar O; Akbulut F
    Int Urol Nephrol; 2024 Mar; 56(3):957-963. PubMed ID: 37880493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
    Melgarejo Segura MT; Morales Martínez A; Yáñez Castillo Y; Arrabal Polo MÁ; Gómez Lechuga P; Pareja Vílchez M; Arrabal Martín M
    Urol Oncol; 2023 Feb; 41(2):109.e1-109.e8. PubMed ID: 36379812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette-Guérin failure.
    Chiancone F; Fabiano M; Carrino M; Fedelini M; Meccariello C; Fedelini P
    Arab J Urol; 2021 Jan; 19(1):86-91. PubMed ID: 33763253
    [No Abstract]   [Full Text] [Related]  

  • 12. [Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients].
    Marquette T; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Verde KL; Dermeche S; Gravis G; Pignot G
    Prog Urol; 2020 Jan; 30(1):35-40. PubMed ID: 31787540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer.
    Sousa A; Piñeiro I; Rodríguez S; Aparici V; Monserrat V; Neira P; Carro E; Murias C; Uribarri C
    Int J Hyperthermia; 2016 Jun; 32(4):374-80. PubMed ID: 26915466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
    Tan WS; Prendergast A; Ackerman C; Yogeswaran Y; Cresswell J; Mariappan P; Phull J; Hunter-Campbell P; Lazarowicz H; Mishra V; Rane A; Davies M; Warburton H; Cooke P; Mostafid H; Wilby D; Mills R; Issa R; Kelly JD
    Eur Urol; 2023 Jun; 83(6):497-504. PubMed ID: 35999119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume center.
    Kastner L; Rieger C; Pfister D; Schmautz M; Storz E; Heidenreich A
    Urol Oncol; 2024 Aug; 42(8):245.e19-245.e26. PubMed ID: 38653592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Immediate Hyperthermic Intravesical Chemotherapy Following Transurethral Resection of Bladder Tumour (I-HIVEC).
    Wong CH; Ko IC; Leung DK; Yuen SK; Chan SY; Yee SC; Chiu PK; Ng CF; Teoh JY
    Eur Urol Oncol; 2024 Dec; 7(6):1171-1174. PubMed ID: 38806344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer.
    Sousa A; Inman BA; Piñeiro I; Monserrat V; Pérez A; Aparici V; Gómez I; Neira P; Uribarri C
    Int J Hyperthermia; 2014 May; 30(3):166-70. PubMed ID: 24697672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance.
    Akbulut F; Pazir Y; Esmeray A; Erbin A; Ozgor F; Sarilar O
    Urologia; 2023 Nov; 90(4):631-635. PubMed ID: 37470319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer.
    Pijpers OM; Hendricksen K; Mostafid H; de Jong FC; Rosier M; Mayor N; de Jong JJ; Boormans JL
    Urol Oncol; 2022 Feb; 40(2):62.e13-62.e20. PubMed ID: 34470725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: a network meta-analysis.
    Zeng N; Xu MY; Sun JX; Liu CQ; Xu JZ; An Y; Zhong XY; Ma SY; He HD; Xia QD; Wang SG
    Front Oncol; 2023; 13():1164932. PubMed ID: 37251942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.